Myovant Sciences Ltd MYOV:NYSE

RT Quote | Last NYSE, VOL From CTA | USD
Last | 11/25/22 EST
26.78quote price arrow down-0.07 (-0.26%)
Volume
189,993
52 week range
7.67 - 26.90
Loading...
  • Open26.82
  • Day High26.85
  • Day Low26.78
  • Prev Close26.85
  • 52 Week High26.90
  • 52 Week High Date11/23/22
  • 52 Week Low7.67
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap2.592B
  • Shares Out96.80M
  • 10 Day Average Volume1.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.25
  • YTD % Change72

KEY STATS

  • Open26.82
  • Day High26.85
  • Day Low26.78
  • Prev Close26.85
  • 52 Week High26.90
  • 52 Week High Date11/23/22
  • 52 Week Low7.67
  • 52 Week Low Date05/09/22
  • Market Cap2.592B
  • Shares Out96.80M
  • 10 Day Average Volume1.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.25
  • YTD % Change72

RATIOS/PROFITABILITY

  • EPS (TTM)-2.00
  • P/E (TTM)-13.36
  • Fwd P/E (NTM)-15.36
  • EBITDA (TTM)-154.238M
  • ROE (TTM)-622.01%
  • Revenue (TTM)333.323M
  • Gross Margin (TTM)74.69%
  • Net Margin (TTM)-56.88%
  • Debt To Equity (MRQ)-69.89%

EVENTS

  • Earnings Date01/24/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Myovant Sciences Ltd

 

Profile

MORE
Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with...
Myrtle Potter
Non-Executive Chairman of the Board
David Marek
Principal Executive Officer, Director
Uneek Mehra
Chief Financial and Business Officer, Principal Financial and Accounting Officer
Matthew Lang
General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Address
Ste 1 3rd Fl, 11/12 St. James's Square
London
SW1Y 4LB
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
RARE
Ultragenyx Pharmaceutical Inc
35.72+1.13+3.27%
FOLD
Amicus Therapeutics Inc
11.49+0.06+0.52%
INSM
Insmed Inc
18.41+0.04+0.22%
BCRX
BioCryst Pharmaceuticals Inc
12.28-0.11-0.89%
ACAD
ACADIA Pharmaceuticals Inc
15.11+0.11+0.73%